Replimune reports early TUDRIQEV launch progress, $307.8 million cash as of Sept. 30, 2026
The company said more than 15 institutions have prescribed its melanoma therapy since first patient delivery on October 6, while its confirmatory Phase 3 trial continues enrolling.
SEC filing